Tectonic Therapeutic, Inc. (TECX) Research

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

Market snapshot

Symbol
TECX
Price
$30.02
Day change
-0.13%
Market cap
$566.5M
P/E ratio
-6.75x
52-week range
14.39-36.03
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$72.00

Peer companies

  • AC Immune S.A. (ACIU)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Amarin Corporation plc (AMRN)
  • Alto Neuroscience, Inc. (ANRO)
  • Cellectis S.A. (CLLS)
  • DBV Technologies S.A. (DBVT)
  • Alpha Tau Medical Ltd. (DRTS)
  • Larimar Therapeutics, Inc. (LRMR)

Recent insider activity

  • Lochner Daniel — A-Award (7500 shares) on 2026-06-11
  • SPRINGER TIMOTHY A — A-Award (10200 shares) on 2026-06-09
  • Tipirneni Praveen P. — A-Award (10200 shares) on 2026-06-09
  • Donenberg Phillip B. — A-Award (10200 shares) on 2026-06-09
  • Vitorovic Stefan — A-Award (10200 shares) on 2026-06-09

Open Tectonic Therapeutic, Inc. (TECX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.